
Radiation oncologist @MSKCancerCenter, aspiring puppy hoarder | @princeton 08 ➡️ @sunydownstate MD/MPH ➡️ @weillcornell
Manhattan, NY
Joined December 2009
- Tweets101
- Following1.1K
- Followers1.2K
- Likes113K
Diana Roth O’Brien, MD MPH retweeted
🚨 We’re hiring at MSK!
🎯 Director, Metastatic Disease Team
👥 Lead ~20 faculty
🧪 Drive innovative trials
🔬 ~50% research time (track-dependent)
🌐 Shape care across @MSKCancerCenter
Help define what’s next in @MSK_RadOnc. 🚀
Contact @seanmmcbride if interested.
Click here for more details: msk.wd108.myworkdayjobs.com/…
Diana Roth O’Brien, MD MPH retweeted
🚨 @MSK_RadOnc is recruiting TWO faculty radiation oncologists for our New Jersey sites!
🔬 Clinical or clinical-research tracks
⏳ 20–40% protected research time
🏥 Join a collaborative, academically focused team at @MSKCancerCenter
Email @seanmmcbride or @simonpowell213 if interested in applying.
Diana Roth O’Brien, MD MPH retweeted
Big congrats to @HimanshuNagarMD on his appointment as our next Chief of External Beam RT for Manhattan and to @LiorBraunstein who will be our inaugural Vice Chair of Clinical AI, Informatics, and Digital Strategy. Their brilliance and skill are huge assets to our department and we're lucky to have 'em! @MSK_RadOnc #radonc
Diana Roth O’Brien, MD MPH retweeted
We are thrilled to welcome our new residents! What an exceptional group and exciting times ahead. Welcome to @MSK_RadOnc!! 🎉 #Match2026 #RadOnc #FutureLeaders
Diana Roth O’Brien, MD MPH retweeted
Hey #radonc!
Trainees seeking an up-to-date treatment guide, attendings interested in learning about MSKCC treatment approaches, and leaders looking to standardize practice across your departments: add this text to your collection! 📖☢️
@LiorBraunstein
link.springer.com/book/10.10…
Diana Roth O’Brien, MD MPH retweeted
“Personalized Approaches to Breast Radiotherapy: Strategies for Treatment Refinement” by Diana A. Roth O’Brien, MD, MPH; and Lior Z. Braunstein, MD hematologyandoncology.net/ar… @drothens @LiorBraunstein @MSKCancerCenter
Diana Roth O’Brien, MD MPH retweeted
Vegan soul food with these amazing physicians. Thank you to my @MSKCancerCenter colleagues for dinner tonight ...and for your support and friendship over the past 5 years. 🙏🙌❤️ #weekendsinNYC
Diana Roth O’Brien, MD MPH retweeted
📢We are overjoyed to announce that Dr @HimanshuNagarMD will be joining @MSKCancerCenter this summer as our Genitourinary Cancer Disease site leader. Dr Nagar is a compassionate clinician & innovative researcher. We are excited to see where he leads our GU #radonc team!
Diana Roth O’Brien, MD MPH retweeted
New from @MSKCancerCenter: The optimal tx strategy for anal adenocarcinoma is evolving. This is the 1st report to describe the safety & feasibility of watch & wait in pts who achieved a clinical complete response after neoadjuvant tx for adeno #ancsm
journals.lww.com/dcrjournal/…
Diana Roth O’Brien, MD MPH retweeted
New in @IJROBP from Dr @drothens @LiorBraunstein & the @MSKCancerCenter #radonc team:
Is #APBI an option for favorable risk #Her2+ #breastCancer?
This study finds excellent short-term local control for HER2+ #bcsm treated with partial breast #radiation
☢️sciencedirect.com/science/ar…
Diana Roth O’Brien, MD MPH retweeted
By 8 weeks after #APBI, most patients reported resolution of symptoms, with 16% reporting residual moderate symptoms. No ascertained salient dosimetric ☢️ parameters were associated with max symptoms or with mod to very severe toxicity. #breastCancer #bcsm
advancesradonc.org/article/S…
Diana Roth O’Brien, MD MPH retweeted
🎙PBI ✖️WBI for early-stage #breastcancer: @JNCI_Now
📌Metanalysis:17,234 👥➡️14 RCTs & 6 observational
- 🥇endpoints: IBR,cosmetics & AEs
📊Findings:
👉5y IBR: PBI = WBI (RR 1.34, 95% CI 0.83—2.18)
👉10y IBR: PBI = WBI (RR 1.29, 95% CI 0.87—1.91)
👉Cosmesis:Insufficient evidence ⚠️
👉Acute AEs: ⬇️PBI✖️WBI
👉 Late AEs: NO sig #
👉IORT:⬆️IBR✖️WBI at 5, 10, >10 y⚠️
#radonc #TreatmentOption
Diana Roth O’Brien, MD MPH retweeted
🔥🔥🔥 Brilliant take on the PROSPECT Trial
🔑🔑🔑 Points
🔑Patient selection (ie. Trial included favorable risk factors with exclusion of T4, N2, distal tumors not amenable to LAR, or within 3 mm of MRF)
🔑 Treatment intent (operative vs. watch & wait)
#ASCO23
👇🏼👇🏼👇🏼
Congrats to the authors of the PROSPECT trial! A tremendous accomplishment. #ASCO23 Some thoughts:
Diana Roth O’Brien, MD MPH retweeted
Listen to Dr. @LiorBraunstein of @MSKCancerCenter, the principal investigator for the @NRGonc “HERO” study, explain why he is excited for this potentially paradigm-shifting trial in HER-2 positive #breastcancer. #bcdm
nrgoncology.org/Home/News/Po…
NRG-BR008, the "HERO" study, was featured as a new trial in our March NRG Currents edition. Learn more about the phase 3 randomized study seeking to optimize use of #radiotherapy in patients with early-stage low-risk, HER2-positive #breastcancer - ow.ly/h6P050NjsUK
Diana Roth O’Brien, MD MPH retweeted
It's a Match! Welcome to @MSKCancerCenter #radonc!! 🥳
🙌Kathryn Hockemeyer MD, PhD
🙌Gideon Haber, MD
🙌Elisa Liu, MD
🙌Revathi Ravella, MD
🙌Alexander Terry, MD
🙌Shoshana Rosenzweig, MD
We're excited to have you join us in New York!
#Match2023 #radoncMatch2023
Diana Roth O’Brien, MD MPH retweeted
🚨New in #AdvancesRO from @MSKCancerCenter #radonc: A tattoo-less setup with surface imaging (AlignRT) appears to be just as accurate for radiation alignment for #breastCancer #PBI --tattoos may not be necessary for #bcsm in the future. @LiorBraunstein
sciencedirect.com/science/ar…
Diana Roth O’Brien, MD MPH retweeted
🚨#OncTwitter #HCWvsHunger RED ALERT🚨
🧪#Feedalizumab @tmprowell
☢️#RadiatePositivity
🩸#BadBlood @MaryCushmanMD
HAVE MERGED TO FORM SUPER GROUP #HemOnculus 💪🧬⚡️
🚨WE ARE WITHIN STRICKING DISTANCE OF #1.
Let's GOOOOOOOOO!!!!
Diana Roth O’Brien, MD MPH retweeted
Did you know @MSKCancerCenter Dr @fumikochino is organizing the team #RadiatePositivity for the annual #HCWvsHunger competition? This year @HCWvsHunger has raised >$450k for food banks to combat #foodinsecurity over the holidays and the #radonc team specifically has raised >$22k!
Diana Roth O’Brien, MD MPH retweeted
Inspired by @DrEmmaHolliday re: GI ASTRO recap, I gave a talk on high-yield BrCa abstracts from #ASTRO22. Too many great studies to include, but here are some highlights. Let me know your thoughts! And what did I miss? @IBCradiation @ChelainG @SFShaitelmanMD @PSchlembachMD 1/6
Diana Roth O’Brien, MD MPH retweeted
NRG/RTOG 1005 - concurrent versus sequential boost #ASTRO22 for breast #radiotherapy. Concurrent boost is non-inferior. No difference in QoL. Concordance with IMPORT High results. This patient-centric trial will save time for patients with #breastcancer. #bcsm #oncoalert




























